Anavar Oxandrolone Raw Powder (2) Raws

Anavar Oxandrolone Raw Powder (2)
Anavar Oxandrolone Raw Powder (2)
  • Model: Steroids-014
  • 1000 Kilogram in Stock

Company Name: Shanghai MeiHua

Certification: ISO9001, SGS, KOSHER

Delivery Time: 5~8 working days

Delivery Way: Domestic Delivery in Canada, Europe

Payment Terms: T/T, Western Union, MoneyGram, Bitcoin


WhatsApp: +8617612057092

Contact US



Oxandrolone Powder For Solving Bone Pain and Weight Loss

Product Name:

Oxandrolone Powder (Anavar)

CAS No.:


Molecular Formula:


Molecular Weight:



99% min

Quality Standard:



White or Almost White Crystalline Powder

Supply Ability:



Store at 8°C-20°C, protect from moisture and light


Anavar Powder Description

First released under the trade name of Anavar in 1960s, it was first marketed for its numerous therapeutic qualities. It had a popular reputation until the FDA began tightening its grips on the anabolic steroid market, causing it to all but disappear in late 1980s. Nearly gone, Anavar has returned as some pharmaceutical companies have begun producing Oxandrolone again. Having risen from the ashes, Anavar is again available for popular consumption.

Anavar Powder Applications

This medication is used to help people regain weight they have lost due to certain medical conditions (such as surgery, chronic infection, trauma, long term use of corticosteroid medication such as hydrocortisone/prednisone).
It is used to relieve bone pain due to bone loss (osteoporosis). Oxandrolone belongs to a class of drugs known as anabolic steroids. These drugs are similar to male hormones made by the body. It is also used non-medically for physique- and performance-enhancing purposes.

Contraindication / Precautions

Oxandrolone is contraindicated in pregnancy and is classified in FDA pregnancy risk category X. Masculinization of the fetus, infertility and teratogenic effects, including embryotoxicity and fetotoxicity, have been reported in female animal offspring when oxandrolone was given in doses 9-times the human dose. These are effects consistent with known effects of other anabolic and androgenic hormones. Oxandrolone should be used cautiously in females of child-bearing potential who may become pregnant. If oxandrolone is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

It is unknown if oxandrolone is excreted into breast milk. Nursing discontinuation or oxandrolone cessation is recommended for mothers who are breast-feeding. Oxandrolone is a synthetic testosterone derivative. Significant exposure to this androgen via breast-feeding may have adverse androgenic effects on the infant and the drug may also interfere with proper establishment of lactation in the mother. Historically, testosterone/androgens have been used adjunctively for lactation suppression. Alternative methods to breast-feeding are recommended in lactating women receiving anabolic/androgenic therapy.

Diabetes mellitus
Androgen therapy can result in hypoglycemia in patients with diabetes mellitus. Oxandrolone can inhibit the metabolism of oral antidiabetic agents and some androgens can lower blood glucose in patients with diabetes. Close monitoring of blood glucose concentrations in patients with diabetes mellitus taking oxandrolone is recommended.

In general, the use of androgens in children should be undertaken only with extreme caution; growth suppression as a result of accelerated bone maturation may occur. The risk of compromised adult growth is greater with oxandrolone use in younger aged patients. X-ray examination of bone age every six months is recommended while on oxandrolone. Of note, anabolic-androgenic steroids can increase height without significantly affecting bone age. Completion of epiphyseal fusion leading to growth cessation does not occur with oxandrolone since it is not aromatized into substances with estrogenic properties.

Breast cancer, prostate cancer, prostatic hypertrophy
Oxandrolone can stimulate the growth of cancerous tissue and is contraindicated in male patients with known prostate cancer or breast cancer. Patients with prostatic hypertrophy should be treated with caution because of the possible development of malignancy. Periodic assessment of prostate specific antigen is recommended for older patients.